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Objective: Endoleak is a common complication of endovascular repair (EVAR) for 
abdominal aortic aneurysm (AAA), but can only be detected through prolonged follow-up 
with repeated aortic imaging. This study examined the potential for circulating matrix 
metalloproteinase-9 (MMP9), osteoprotegerin (OPG), D-dimer, homocysteine (HCY) and C-
reactive protein (CRP) to act as diagnostic markers for endoleak in AAA patients undergoing 
elective EVAR.  
Methods: Linear mixed effects models were constructed to assess differences in AAA 
diameter after EVAR, between groups of patients who did, and did not develop endoleak 
during follow-up, adjusting for potential confounders. Circulating MMP9, OPG, D-dimer, 
HCY and CRP concentrations were measured in pre- and post-operative plasma samples. The 
association of these markers with endoleak diagnosis was assessed using linear mixed effects 
adjusted as above. The potential for each marker to diagnose endoleak was assessed using 
receiver operator characteristic (ROC) curves. 
Results: Seventy-five patients were included in the current study, 24 of whom developed an 
endoleak during follow-up. Patients with an endoleak had significantly large AAA sac 
diameters than those that did not have an endoleak. None of the assessed markers showed a 
significant association with endoleak. This was confirmed through ROC curve analyses 
indicating poor diagnostic ability for all markers. 
Conclusions: Circulating concentrations of MMP9, OPG, D-dimer, HCY and CRP were not 





Abdominal aortic aneurysm (AAA) affects ~2% of men over the age of 65 years, and is a 
leading cause of mortality in the elderly [1-5]. The main current treatment for AAA is 
endovascular repair (EVAR). This involves the endovascular placement of stent grafts to 
isolate the AAA wall from the main aortic blood flow [6]. Despite low perioperative 
morbidity and mortality, the durability of EVAR is of concern as a high proportion of patients 
have continued perfusion of the AAA sac or endoleak [7-9]. Endoleak is the most common 
complication of EVAR, and may occur due to incomplete seal of the proximal or distal ends 
of the graft (type I endoleak), reverse flow through collateral arteries (type II endoleak), or 
stent defects (types III-V) [10, 11]). Patients undergoing EVAR require long-term monitoring 
involving computed tomography and/or ultrasound to detect endoleak [12]. This has several 
disadvantages including repeated exposure of the patient to ionising radiation, and the 
requirement for specialist infrastructure and trained staff which negatively impacts on the 
cost-effectiveness of EVAR [10].  
 
It has been suggested that the current disadvantages associated with imaging-based 
monitoring may be overcome through the discovery of blood-borne markers to diagnose 
endoleak, which may ultimately reduce the need for post-EVAR imaging [10]. This is based 
on the theory that successful EVAR will place a physical barrier between the aneurysmal wall 
and the bloodstream, thereby reducing the circulating concentrations of AAA-secreted 
proteins. Continued perfusion of the AAA sac due to endoleak would therefore be reflected 
by persistent elevations or spikes in the circulating concentration of AAA biomarkers during 
follow-up. Aortic inflammation, excessive extracellular matrix remodeling and thrombosis 
are implicated in AAA pathogenesis, suggesting that circulating markers of these processes 
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may be useful in diagnosing endoleak [4, 13-15]. To date, relatively few studies have 
specifically investigated the association of blood-borne markers with the presence of 
endoleak, and the potential value of a blood marker-based approach for EVAR surveillance 
remains unclear. The aim of the current study was therefore to assess the association of 
circulating concentrations of 3 putative biomarkers previously associated with AAA presence 
(matrix metalloproteinase-9 [MMP9], osteoprotegerin [OPG], and D-dimer), and two 
routinely assessed blood parameters (homocysteine [HCY] and C-reactive protein [CRP]) 
with endoleak, in a cohort of patients undergoing elective EVAR. 
 
METHODS 
Patient recruitment and follow-up: This study analysed a subset of patients recruited to the 
Australian EVAR outcomes modelling trial which has been described in detail in previous 
publications [16-18]. For the purposes of this study, patients undergoing EVAR were 
followed prospectively to monitor outcome. To be eligible for inclusion in the current study, 
patients were required to have i) undergone elective EVAR to repair an AAA; ii) received at 
least 1 infra-renal aortic computed tomography angiogram pre, and  post-EVAR; and iii) 
provided a fasting blood sample pre-, and at least 3 months post-EVAR. All patients provided 
written informed consent upon recruitment, and the study was conducted under institutional 
ethics approval in accordance with the guidelines of the Declaration of Helskini. Follow-up 
was conducted according to institutional guidelines. All patients underwent imaging at 1 
and/or 6 months after EVAR, followed by repeated scans at 12, 24 and 36 months. 
 
Diagnosis of endoleak: This was performed through assessment of computed tomographic 
angiography as a contrast blush inside the AAA sac after EVAR. To be included in the 
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current study this endoleak needed to have been confirmed on at least two occasions during 
follow-up. 
 
Data collection and definitions used: Characteristics collected from each patients included 
age at the time of operation (referred to as age), sex, history of smoking, hypertension, 
diabetes mellitus, ischaemic heart disease (IHD) and prescribed medications. Height and 
weight were measured and were used to calculate body mass index (BMI; calculated as 
weight in kg/ height in metres2). For the purposes of this study patients were classified as 
having never or ever smoked. Diabetes mellitus and hypertension were defined by a history 
of diagnosis or treatment for these conditions. Serum lipids (total cholesterol, high density 
lipoprotein cholesterol, low density lipoprotein cholesterol and triglycerides), HCY, CRP and 
creatinine were measured in hospital pathology laboratories using previously described 
methods [19]. 
 
Assessment of circulating AAA biomarkers: Commercial ELISAs were used to measure 
plasma concentrations of MM9, OPG (R&D Systems, both using plasma collected in EDTA-
coated tubes) and D-dimer (Technozym, using plasma collected in Sodium citrate-coated 
tubes) according to the manufacturer’s directions. We have previously used these kits to 
analyse clinical samples with excellent reproducibility [20-22]. 
 
Statistical analyses: Demographic differences between patient groups were compared by 
univariate statistics using the SPSS software package (version 23.0, IBM, Armonk, NY, 
USA). Continuous demographic variables were compared using the Mann-Whitney U test 
and were presented as median and inter-quartile range. Nominal variables were presented as 
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count and percent, and were compared using the Chi-squared test. Longitudinal comparisons 
to assess changes in AAA diameter and circulating biomarker concentrations were performed 
using random-intercept linear mixed effects models using the freely available R statistical 
package as previously described [23]. Initially this was assessed in unadjusted analyses 
including, endoleak presence and time as fixed effects, and variation between individual 
patients as a random effect (unadjusted models). Time was treated as a factorial variable in 
models assessing AAA diameter as images were acquired at set intervals post-EVAR. For 
models assessing biomarker concentrations, time was considered a continuous variable owing 
to variations in blood collection intervals following EVAR. For these analyses MMP-9, D-
dimer, OPG and CRP concentrations were log-transformed to conform to model assumptions. 
We then assessed the association of biomarkers with endoleak presence in multivariable 
linear mixed effects models including age, prescription for statins and hypertension as 
additional fixed effects, based on observations of significant differences for these variables 
between groups on univariate comparisons (adjusted models). Model fit was assessed by 
examining the distribution of residuals using qq-normal plots, and scatter plots of the fitted 
values vs standardized residuals. No issues with residual distributions were observed for the 
models reported. To minimize the potential for over-parameterisation, goodness of fit for 
each model was assessed using Akaike’s second order Information Criterion (AICc), whereby 
lower scores denote better model fit. The potential for the assessed blood markers to diagnose 
endoleak was further examined using receiver operator characteristic (ROC) curves generated 
for the unadjusted and adjusted models. For these analyses, post-operative plasma 
concentrations of each marker were used. The difference in AUC of the unadjusted and 
adjusted analyses was assessed using DeLong’s test for paired ROC curves. The additive 
benefit of considering each of the biomarkers in diagnosing endoleak was assessed in 
sensitivity analyses, which comparing the AUC of each adjusted model to that of a base 
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model which included the relevant covariates (age, hypertension and statin prescription), but 
omitted the blood marker. 
 
For all analyses, p-values <0.05 were considered statistically significant.  
 
Sample size calculation: Sample sizes for the current study were calculated based on previous 
data from studies assessing the association of circulating MMP9 concentrations with 
endoleak diagnosis. Findings from our recent meta-analysis indicated that circulating 
concentrations of MMP9 would be markedly higher in the endoleak patients than the controls 
[10]. One of the largest studies in this field was conducted by Sangiorgi et al. who reported 
that circulating MMP9 concentrations were 40.2 (+20.9) ng/mL in patients with endoleak, 
and 23.6 (+10.4) in non-endoleak controls [24]. Assuming similar data in the current study, 
sample size calculations suggested this difference could be detected with 80% power by 
including 13 cases and 25 controls (effect size 1.01, 2-tailed alpha 0.05). Final participant 
numbers in the current study exceeded these predicted sample sizes, and we therefore 




Pre-operative characteristics of patients who did, and did not have endoleak within 6 
months of EVAR 
A total of 75 patients undergoing EVAR fulfilled the inclusion criteria for  the current 
analysis. The majority (86.7%) of patients received aorto-bi-iliac stents, the remainder 
received aorto-uni-iliac grafts (6.7%), or fenestrated devices (5.3%). Stent type was not 
reported for 1 patient. During follow-up, 24 (32.0%) patients were identified to have an 
endoleak. Of these, 2 (8.3%), were type-I endoleaks, 20 (83.3%), were type-II endoleaks, and 
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1 patient developed both type-I and type-III endoleaks. The cause of endoleak could not be 
ascertained for 1 patient. Endoleak was not associated with the type of stent used. Compared 
to those who did not develop endoleak, patients who developed endoleak were older 
(P=.023), were more likely to be prescribed statins, with concomitantly lower circulating 
LDL-C concentrations (both P=.036), and had higher circulating HCY concentrations prior to 
operation (Table I). The prevalence of hypertension was also higher in the endoleak group, 
which although not statistically significant (P=.051), was considered a confounding variable 
in subsequent analyses. 
 
Comparing changes in post-EVAR AAA diameter in groups of patients who did and did 
not develop endoleak 
Figure 1 shows AAA diameter measured over time for patients who did, and did not develop 
endoleak during follow-up. Linear mixed effects modelling demonstrated significant 
differences in changes in AAA diameter between the groups over the follow-up period 
(P<.001; Figure 1 and Supplementary File I). More specifically, modelling analyses 
demonstrated that AAA diameters were similar between groups at the time of EVAR, and 1 
month thereafter, but were significantly larger in the endoleak group at 6 months after EVAR 
and for the remainder of follow-up. 
 
Testing the associations of circulating markers with endoleak presence 
Circulating concentrations of D-dimer, MMP9, OPG, HCY and CRP were measured in 
fasting blood samples collected from all patients at recruitment (pre-EVAR), and during 
follow-up (post-EVAR; Table II). Plasma D-dimer concentrations increased in all patients 
after EVAR (P<.001 for patients who did and did not suffer endoleak). Similarly, a trend 
towards increased plasma concentrations of HCY and OPG after EVAR was also observed 
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for both groups, however significance was only observed for patients who did not develop 
endoleak. No differences in pre- and post-operative plasma concentrations of MMP9 and 
CRP were observed for either group. Temporal changes in the plasma concentrations of the 
assessed markers were compared between patient groups using linear mixed effects models. 
No significant association of any of the assessed blood markers with endoleak was observed 
during follow-up, evidenced by the absence of robust interactions between time and endoleak 
status in the models (Table II and Supplementary File II).  
 
Investigating the potential for the assessed biomarkers to diagnose endoleak 
The ability for post-operative concentrations for each of the assessed markers to identify 
patients suffering endoleak was investigated using ROC curves (Table III). The AUC for 
each assessed marker was low when assessed alone (range 0.469-0.624), but markedly 
increased when considered in conjunction with age, statin use and hypertension (adjusted 
models; range of AUC for adjusted model: 0.760-0.844; P-value for improvement in AUC 
<.050 for all markers except D-dimer). Sensitivity analyses, however, demonstrated that this 
increase in AUC was largely attributable to consideration of the covariates, rather than the 




The current study investigated the association of several markers for AAA with endoleak 
diagnosis in a cohort of prospectively followed patients undergoing EVAR. AAA sac 
diameters of the patients who developed endoleak were significantly higher than those who 
had successful EVAR, however, none of the examined biomarkers were associated with 




MMP9 is a zinc-dependent gelatinase which has been implicated in AAA development and 
progression through proteolytic degradation of the aortic extracellular matrix [10]. Several 
prior investigations have assessed the relationship between circulating MMP9 concentrations 
and endoleak presence, although the significance and extent of the reported associations vary 
between studies [24-28]. A recent meta-analysis of these studies identified a significant 
positive association of plasma MMP9 concentration with endoleak presence [10]. The 
findings of the meta-analysis are contradicted by those of the current study as no relationship 
between endoleak diagnosis and circulating MMP9 concentration was observed. The reasons 
for this discrepancy may in part be related to differences in populations studied or different 
handling of blood samples and assessment methods. Monaco et al. for example specifically 
investigated endoleaks following EVAR for descending thoracic aortic aneurysm, compared 
to AAA included in the current study, and differences in disease pathophysiology may 
complicate direct comparison of their findings and ours [25]. Sample sizes used in the current 
study were larger than those of the previous reports which assessed MMP9 in AAA patients 
with endoleak [24, 26-28], suggesting greater analytical power, although further studies 
employing large patient cohorts are needed to more definitively assess the association of 
circulating MMP9 concentrations with endoleak presence. 
 
Numerous reports have suggested that circulating D-dimer concentrations are elevated in 
patients with AAA [20, 29-31], attributable in part to the formation of a large non-occlusive 
thrombus within the aneurysmal sac [32]. Surprisingly, the association of plasma D-dimer 
concentration with endoleak has only been directly examined in a single study which reported 
that circulating D-dimer concentrations were significantly higher in patients suffering type 1 
endoleak (compared to non-endoleak controls), and were highly diagnostic for type 1 
endoleak following ROC analysis [33]. Importantly, sample sizes in this previous study were 
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extremely small (n=4 for the type 1 endoleak group), making it hard to draw firm conclusions 
from the presented data. Indeed, these findings are challenged by that of a larger study 
suggesting that post-EVAR plasma fibrinogen degradation product concentrations (of which 
D-dimer is a component) are lower in patients with endoleak than those without [34]. Data 
from the current study contrast with both of these reports. We observed no association of 
plasma D-dimer concentration with endoleak, but did note significant increases in circulating 
D-dimer titres for both groups following EVAR. The reasons for this remain unclear, 
although previous studies have independently reported an increase in circulating D-dimer 
concentration following EVAR [35-38]. This is arguably due to thrombosis of the AAA sac 
around the stent graft, although some studies suggest that D-dimer titres return to basal levels 
within 1 month [35], whereas others report an elevation which persists for up to 6 months 
[36-38]. The median time to post-operative blood collection for the current study was ~8 
months for the whole cohort. This therefore suggests a prolonged elevation in circulating D-
dimer concentration following EVAR, which therefore limits the ability for this marker to 
diagnose endoleak. 
 
OPG is a member of the tumour necrosis factor receptor super-family, [39], and we and 
others have reported a positive association of circulating OPG concentration with AAA 
presence [21, 40, 41]. To our knowledge, this is the first study to directly assess the 
association of OPG with endoleak presence. Our data identified a post-operative increase in 
median plasma OPG concentration in the patients who did not develop endoleak, however, no 
significant inter-group difference was observed during follow-up. This is further supported by 
the secondary ROC analyses which indicated low potential for OPG to act as a biomarker for 
endoleak in the current cohort. The reasons for the observed post-operative increase in 
plasma OPG in the no endoleak group remain unclear. Two surgical investigations have 
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reported significant post-operative increases in circulating OPG concentration for AAA 
patients undergoing aneurysm repair [41, 42].  
 
The final two markers assessed (CRP and HCY) are commonly measured as part of patient 
care, and the availability of pre- and post-operative measurements for these markers provided 
the opportunity to assess their association with endoleak. CRP is an acute phase protein 
which is used to assess systemic inflammation, and has been suggested to be associated with 
AAA presence in a number of studies (discussed in [13, 15]). To our knowledge, the 
relationship between CRP and endoleak has not been directly assessed, although prior data 
suggest that CRP concentrations may naturally increase in patients following EVAR [34]. De 
Haro and colleagues recently reported a positive association between AAA sac expansion 
after EVAR and elevations in CRP in a large patient series, although they indicated that none 
of these patients had demonstrable endoleaks [43]. Interpreting the findings of their study is 
difficult for two reasons. Firstly, De Haro et al. report post-operative AAA sac expansion in 
63% (n=120) of their patients which appears unusually high. Secondly, the extent of annual 
AAA sac expansion appeared relatively low (cut-off for ‘fast’ expanders defined as >5.7%), 
which may be within the range of measurement error for most imaging modalities, 
complicating patient stratification [44, 45]. In contrast we observed no increase in post-
operative CRP concentrations for any of our patients, and further investigations into the 
association of CRP with endoleak status are warranted to validate this finding.  
 
Univariate analyses demonstrated that preoperative HCY levels were markedly higher in 
patients who subsequently developed endoleak, however, no association of this protein with 
endoleak presence was observed during follow-up. No other papers have directly investigated 
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the association of HCY concentration with endoleak, and it is therefore not possible to 
compare this finding with other sources. However, our observations tentatively suggest that 
HCY might not directly influence endoleak susceptibility, but may be a surrogate marker for 
other factors which contribute to post-operative risk. HCY is a surrogate marker of 
atherosclerotic severity; moreover, a higher proportion of patients who developed endoleak 
were prescribed statins [46, 47]. Taken together, these findings suggest that the extent of 
atherosclerosis may have been more severe in the patients who developed endoleak. Thus, it 
is tempting to speculate that a higher atherosclerotic burden may have compromised stent 
placement and seal during EVAR leading to eventual endoleak, although data to specifically 
test this hypothesis were not available.  
 
The findings of the current study should be considered in light of its limitations. Firstly, the 
number of participants was relatively low, although the current cohort is larger than most of 
the studies which have previously published in this area. Moreover, sample sizes included in 
these analyses exceeded those suggested by a priori sample size calculations suggesting that 
the study was adequately powered to detect previously suggested differences between groups. 
Secondly, owing to small sample sizes, we were underpowered to assess the association of 
each marker with specific endoleak sub-types, or compare the expression of circulating 
markers from patients with endoleak in whom AAAs continued to expand, with those whose 
AAA did not increase in size. The majority of patients assessed here had type-II endoleaks 
which may result from reperfusion of the AAA sac with blood at a relatively low pressure 
(discussed by [48, 49]), possibly limiting the potential for AAA-secreted markers to enter the 
bloodstream. It is therefore possible that circulating concentrations of the assessed 
biomarkers may be more markedly elevated in patients suffering higher-pressure endoleaks 
although targeted studies are needed to explore this further. Thirdly, some baseline 
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differences in key characteristics were observed between the groups, however, the impact of 
this was mitigated by performing multivariable analyses. Finally, the timing of collection of 
the post-operative blood samples differed between patients, and this may have contributed to 
the observed negative findings, however, the impact of this was minimized in several ways. 
Firstly our prior meta-analysis demonstrated that circulating MMP9 concentrations were 
significantly higher in patients with endoleak compared to those who did not, in samples 
collected 3 months after EVAR (consistently reported across multiple studies) [10]. 
Accordingly, we analysed post-operative blood samples which were collected at least 3 
months after EVAR to maximize the chances of detecting a difference between groups. In 
addition, we ensured that all patients had an endoleak at the time the post-operative samples 
were collected, and the analysed blood samples were therefore representative of the 
phenotype of interest. Moreover, time was included as a continuous variable in our linear 
mixed effects analyses. Model diagnostics demonstrated that inter-patient differences in 
follow-up were handled appropriately in our longitudinal analyses.  
 
Conclusions 
In summary, the current study assessed the potential for circulating concentrations of MMP9, 
OPG, D-dimer, CRP and HCY to act as diagnostic markers for endoleak. None of the 
assessed markers showed any association with endoleak status, however circulating D-dimer 
concentrations were markedly increased in all patients following EVAR. Collectively these 
findings suggest that the assessed markers have little potential to influence current post-
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Table I – Comparison of pre-operative characteristics between groups of AAA patients who did and did not develop endoleak following EVAR 








Age (y) 74.2 (67.3-80.1) 72.8 (66.1-78.7) 78.4 (73.2-80.6) .023 
Male sex  67 (89.3%) 47 (92.2%) 20 (90.9%) .248 
BMI 27.1 (24.7-29.7) 26.5 (24.7-30.6) 27.4 (24.8-29.0) .955 
AAA diameter (mm) 55.0 (52.0-61.0) 55.0 (52.0-61.0) 54.0 (51.0-59.5) .446 
Months from EVAR to biomarker blood sampling 
(months) 
8.3 (7.2-10.3) 8.4 (7.2-10.3) 8.1 (7.3-10.5) .896 
Stent type [1]: 
Aorto-bi-iliac 65 (86.7%) 46 (90.2%) 19 (79.2%)  
.272 Aorto-uni-iliac crossover 5 (6.7%) 2 (3.9%) 3 (12.5%) 
Fenestrated 4 (5.3%) 2 (3.9%) 2 (8.3%) 
History of: 
Ever smoking 59 (78.7%) 43 (84.3%) 16 (66.7%) .082 
Hypertension 62 (82.7%) [1] 39 [1] (76.5%) 23 (95.8%) .051 
Diabetes 13 (17.3%) [1] 9 (17.6%) [1] 4 (16.7%) .888 
IHD 34 (45.3%) 21 (41.2%) 13 (54.2%) .292 
Prescription for: 
Beta blockers 30 (40.0%) 21 (41.2%) 9 (37.5%) .762 
Statins 50 (66.7%) 30 (58.8%) 20 (83.3%) .036 
Warfarin 7 (9.3%) [2]  7 (13.7%) [1] 0 (0.0%) [1] .059 
Circulating concentrations of: 
Total cholesterol (mmol/L) 3.8 (3.3-4.6) [11] 3.8 (3.3-4.6) [9] 3.5 (3.2-4.5) [2] .288 
HDL-C (mmol/L) 1.0 (0.8-1.3) [11] 1.0 (0.8-1.2) [9] 1.1 (0.9-1.3) [2] .143 
LDL-C (mmol/L) 2.0 (1.6-2.6) [11] 2.3 (1.8-2.7) [9] 1.9 (1.5-2.2) [2] .036 
Triglycerides (mmol/L) 1.3 (1.0-1.9) [11] 1.4 (1.0-1.8) [9] 1.3 (1.0-2.1) [2] .932 
C-reactive protein (mg/L) 2.2 (1.1-5.8) [15] 2.4 (1.1-8.5) [13] 2.0 (1.7-4.7) [2] .994 
Homocysteine (mol/L) 12.0 (10.0-16.3) [13] 12.0 (10.0-14.0) [10] 16.0 (11.3-19.2) [3] .020 
Creatinine (µmol/L) 88.5 (72.8-107.0) [1] 89.0 (73.0-102.0) 88.0 (72.0-114.0) [1] .833 
 
IHD: Ischaemic heart disease; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol. Numbers in square brackets refer to 
number of missing data points. Bold text denotes statistically significant differences between the groups.
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Comparisons within groups (Wilcoxon matched-pairs signed rank test) Comparison between groups 
(linear mixed effects models) No endoleak group (n=51) Endoleak groups (n=24) 
Pre-op Post-op P-value Pre-op Post-op P-value Unadjusted P-value 
Adjusted P-
value 




















<.001 .382 .312 



































.346d .449 .448 
Circulating concentrations of each marker are shown as median and inter-quartile range. Numbers in square brackets denote number of missing 
datapoints. 
Linear mixed effects p-values relate to the interaction between time and endoleak status. Unadjusted p-values relate to models including the 
assessed blood marker as the sole covariate. Adjusted p-values related to models incorporating the blood marker, age at the time of operation, 
prescription for statins and history of hypertension.  





Table III – ROC curve analyses assessing the ability of post-operatively measured markers to diagnose endoleak 
 
Blood marker 
Unadjusted model Adjusted modela Comparison between 
Adjusted and  
unadjusted (P-value) 
Comparison with base modelb 
(P-value) AUC 95% CI AUC 95% CI 
MMP9 0.469 0.331-0.607 0.760 0.642-0.878 .002 .857 
OPG 0.523 0.378-0.669 0.771 0.657-0.885 .007 .561 
D-dimer 0.624 0.489-0.760 0.761 0.644-0.878 .137 .808 
C-reactive protein 0.538 0.366-0.710 0.844 0.738-0.951 .003 .288 
Homocysteine 0.590 0.708-0.772 0.841 0.726-0.955 <.001 .324 
 
a Adjusted model comprises the circulating marker, age at operation, history of hypertension and prescription for statins based on differences 
observed between groups upon recruitment (see Table I). 
b Base model comprises age at operation, history of hypertension and prescription for statins. P-values relate to the comparison of adjusted blood 






Figure 1. A) Comparisons of AAA diameter following EVAR in groups of patients who did 
(red squares) and did not (blue circles) develop endoleak during follow-up. Data are shown 
as mean and standard error for each group. P value refers to the overall difference of AAA 
diameter between groups during follow-up as assessed by linear mixed effects modelling. 
Asterisks show significant differences between groups for each time point evidenced by p-
values <0.05 within the linear mixed effects model. B) Details of the number of patients 
included for each assessed timepoint. 
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Circulating biomarkers are not asasociated with endoleaks after endovascular repair of 
abdominal aortic aneurysms 
 
SUPPLEMENTARY MATERIAL – DETAILED OUTPUT OF LINEAR MIXED EFFECTS MODELS 
 
Contents: 
Supplementary file 1 – Output from linear mixed effects analyses detailing changes in AAA diameter 
during follow-up. 
 
Supplementary file 2 – Output from linear mixed effects analyses detailing changes in circulating 
MMP9, D-dimer, OPG, HCY and CRP concentrations in patients who do or do not have endoleak. 
 
Preface 
Linear mixed effects models were created and run using the publically available R software package - 
data below show the raw output for all models. For each mode, the variable of interest was assessed 
in an unadjusted model, or an adjusted model incorporating covariates selected based on baseline 
differences identified between cohorts (age at operation, hypertension and statin use). In unadjusted 
analyses, endoleak presence and time are considered as fixed effects, and variation between patients 
was considered a random effect. In adjusted models, age at operation, hypertension and statin use 





Supplementary file 1 – Output from linear mixed effects analyses detailing changes in AAA 
diameter during follow-up. 
 


















































































































































































Supplementary file 2 – Output from linear mixed effects analyses detailing changes in 
circulating MMP9, D-dimer, OPG, HCY and CRP concentrations in patients who do or do not 
have endoleak. 
 
Note – for biomarker assessments, time is treated as a continuous variable. Plasma concentrations of MMP9, D-
dimer, OPG and CRP required log-transformation to conform to model assumptions. 
 




































































































































































































































































































































































































































Assessing CRP – Adjusted analysis 
CRP.endoleak.lme3<‐lme(log.CRP~Endoleak_ever*Time+ 
                             Age_at_op_years+Cohypertension+MedStatin, 
                       random = ~1|TrialID,  
                       data=Endoleak.HCY.CRP, na.action='na.omit') 
## Linear mixed‐effects model fit by REML 
##  Data: Endoleak.HCY.CRP  
##        AIC      BIC    logLik 
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##   368.8461 392.8171 ‐175.4231 
##  
## Random effects: 
##  Formula: ~1 | TrialID 
##         (Intercept)  Residual 
## StdDev:   0.7011283 0.8748673 
##  
## Fixed effects: log.CRP ~ Endoleak_ever * Time + Age_at_op_years + 
Cohypertension +      MedStatin  
##                         Value Std.Error DF    t‐value p‐value 
## (Intercept)         1.6976831 1.1664713 58  1.4554007  0.1509 
## Endoleak_ever      ‐0.0712491 0.3346794 58 ‐0.2128877  0.8322 
## Time               ‐0.0296947 0.0350143 48 ‐0.8480748  0.4006 
## Age_at_op_years    ‐0.0119860 0.0163173 58 ‐0.7345560  0.4656 
## Cohypertension     ‐0.0037226 0.3948664 58 ‐0.0094276  0.9925 
## MedStatin           0.1987483 0.2880057 58  0.6900846  0.4929 
## Endoleak_ever:Time  0.0450457 0.0588788 48  0.7650592  0.4480 
##  Correlation:  
##                    (Intr) Endlk_ Time   Ag_t__ Chyprt MdSttn 
## Endoleak_ever       0.061                                    
## Time               ‐0.104  0.319                             
## Age_at_op_years    ‐0.880 ‐0.318 ‐0.001                      
## Cohypertension     ‐0.143  0.228  0.014 ‐0.172               
## MedStatin          ‐0.094  0.223  0.029 ‐0.147 ‐0.273        
## Endoleak_ever:Time  0.104 ‐0.473 ‐0.595 ‐0.044  0.004 ‐0.026 
##  
## Standardized Within‐Group Residuals: 
##        Min         Q1        Med         Q3        Max  
## ‐2.2626440 ‐0.4962737 ‐0.1164732  0.3893526  3.8035212  
##  
## Number of Observations: 113 
## Number of Groups: 63 
anova(CRP.endoleak.lme3) 
##                    numDF denDF  F‐value p‐value 
## (Intercept)            1    58 68.57790  <.0001 
## Endoleak_ever          1    58  0.05982  0.8076 
## Time                   1    48  0.27171  0.6046 
## Age_at_op_years        1    58  0.33129  0.5671 
## Cohypertension         1    58  0.03550  0.8512 
## MedStatin              1    58  0.50414  0.4805 
## Endoleak_ever:Time     1    48  0.58532  0.4480 
